Over-the-Counter Vitamin-like Compound May Slow Progression of Parkinson's Disease

A large-scale, multicenter clinical trial in the United States and Canada has been initiated to determine whether a vitamin-like compound, called coenzyme Q10, in high doses, can slow the progression of Parkinson's disease (PD), a neurodegenerative disorder that affects approximately one million people in the United States.

"At present, the very best therapies we have for Parkinson's can only mask the symptoms--they do not alter the underlying disease,” said neurologist Dr. Katie Kompoliti, a specialist in movement disorders from Rush University Medical Center (Chicago, IL, USA). "Finding a treatment that can slow the degenerative course of Parkinsons' is the holy grail of Parkinson's research.”

The substance being tested, coenzyme Q10 is produced naturally in the body and is an important link in the chain of chemical reactions that generate energy in mitochondria, the "powerhouses” of cells. The enzyme is also a potent antioxidant--a chemical that "mops up” potentially harmful chemicals generated during normal metabolism. Several studies have shown that Parkinson's patients have impaired mitochondrial function and low levels of coenzyme Q10. Moreover, laboratory research has demonstrated that coenzyme Q10 can protect the area of the brain damaged in Parkinson's.

The phase III clinical trial, a large, randomized study with a control group, follows an earlier investigation that tested several doses of coenzyme Q10 in a small group of patients with early-stage Parkinson's disease. The highest dose, 1,200 mg, appeared promising. Over the course of 16 months, patients taking this dose experienced significantly less decline than other patients in motor (movement) function and ability to perform activities of daily living, such as feeding or dressing themselves. However, researchers involved in the study, including Dr. Kompoliti, were cautious about their findings, citing the need for a more extensive review to confirm the results.

In the present trial, funded by the U.S. National Institutes of Health and the National Institute of Neurological and Disorders and Stroke (Bethesda, MD, USA), 600 patients will be enrolled at 60 centers in the United States and Canada. Two dosages of coenzyme Q10 are being tested, 1,200 mg and 2,400 mg, delivered in maple nut-flavored chewable wafers that also contain vitamin E.

Participants in the study will be evaluated periodically over 16 months for symptoms of Parkinson's disease, including tremor, stiffness of the limbs and trunk, impaired balance and coordination, and slowing of movements. They will also be assessed for ability to perform daily activities, overall quality of life, and need to take medications to alleviate symptoms.

Related Links:
Rush University Medical Center